Anthony R. Mato
- Oncology top 1%
- CAR-T cell therapy research 18
- Viral-associated cancers and disorders 10
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 31
-
- Lymphoma Diagnosis and Treatment 56
- Hematology top 2%
- Multiple Myeloma Research and Treatments 7
- Chronic Myeloid Leukemia Treatments 7
- Acute Myeloid Leukemia Research 6
- Immunology top 5%
-
- CNS Lymphoma Diagnosis and Treatment 9
- Co-authors
- Jakub SvobodaStephen J. SchusterSunita D. NastaDaniel J. LandsburgElise A. ChongSimon F. LaceyCarl H. JuneBruce L. Levine
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (16 papers)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Anthony R. Mato
82 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Oncology 1.9k
- Genetics 746
- Pathology and Forensic Medicine 1.1k
- Hematology 383
- Immunology 619
Countries citing papers authored by Anthony R. Mato
This map shows the geographic impact of Anthony R. Mato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony R. Mato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony R. Mato more than expected).
Fields of papers citing papers by Anthony R. Mato
This network shows the impact of papers produced by Anthony R. Mato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony R. Mato. The network helps show where Anthony R. Mato may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anthony R. Mato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 9 | |
| 2 | 2018 | 32 | |
| 3 | 2018 | 11 | |
| 4 | 2017 | 4 | |
| 5 | 2017 | 17 | |
| 6 | 2017 | 4 | |
| 7 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomasbreakdown → | 2017 | 1266 |
| 8 | 2017 | 12 | |
| 9 | 2015 | 46 | |
| 10 | 2015 | 113 | |
| 11 | 2014 | 19 | |
| 12 | 2014 | 48 | |
| 13 | 2013 | 1 | |
| 14 | PEG-Asparaginase Based Multidrug Chemotherapy is Effective for Refractory Disseminated Extranodal NK/T-Cell Lymphoma With Leptomentigeal Involvement: A Clinical Case Report and Review of Literature | 2013 | 1 |
| 15 | 2012 | 1 | |
| 16 | 2011 | 37 | |
| 17 | 2008 | 29 | |
| 18 | 2008 | 4 | |
| 19 | 2006 | 29 | |
| 20 | 2006 | 49 |
About Anthony R. Mato
Anthony R. Mato is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology, having authored 85 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (56 papers), Chronic Lymphocytic Leukemia Research (31 papers), CAR-T cell therapy research (18 papers), Viral-associated cancers and disorders (10 papers), CNS Lymphoma Diagnosis and Treatment (9 papers), Multiple Myeloma Research and Treatments (7 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). The work is most often cited by research in Oncology (1.9k citations), Genetics (746 citations) and Pathology and Forensic Medicine (1.1k citations). Anthony R. Mato has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Jakub Svoboda, Stephen J. Schuster, Sunita D. Nasta, Daniel J. Landsburg, Elise A. Chong, Simon F. Lacey, Carl H. June, Bruce L. Levine, J. Joseph Melenhorst and David L. Porter. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.